Phase IIb dose/regimen study of GW873140 with Kaletra in antiretroviral-naive HIV-1 infection

Phase 2, randomised, open-label trial of aplaviroc in Human immunodeficiency virus infection type 1 (2 arms), sponsored by GSK. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <400 copies/mL remaining on randomized treatment regimen through Week 12. Started Feb 2005; status: terminated.